Detalhe da pesquisa
1.
Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival.
Eur Radiol
; 33(10): 7284-7293, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37099174
2.
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer.
J Clin Oncol
; 42(11): 1311-1321, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38207230
3.
Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors.
Cancer Discov
; 2024 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38564707
4.
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
J Thorac Oncol
; 18(6): 731-743, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36775193
5.
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC.
J Thorac Oncol
; 18(11): 1524-1537, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37247843
6.
Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer.
Clin Cancer Res
; 29(13): 2540-2550, 2023 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37097610
7.
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
J Thorac Oncol
; 17(3): 399-410, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34740862
8.
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations.
J Immunother Cancer
; 10(2)2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35173031
9.
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.
JAMA Oncol
; 8(8): 1160-1168, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35708671
10.
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer.
J Immunother Cancer
; 9(11)2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34824161